2023-01-012023-12-312023-12-31false09930790Sahli Medical Limited2024-04-0286220iso4217:GBPxbrli:pure099307902023-01-01099307902023-12-31099307902023-01-012023-12-31099307902022-01-01099307902022-12-31099307902022-01-012022-12-3109930790bus:SmallEntities2023-01-012023-12-3109930790bus:AuditExempt-NoAccountantsReport2023-01-012023-12-3109930790bus:FullAccounts2023-01-012023-12-3109930790bus:PrivateLimitedCompanyLtd2023-01-012023-12-3109930790core:WithinOneYear2023-12-3109930790core:AfterOneYear2023-12-3109930790core:WithinOneYear2022-12-3109930790core:AfterOneYear2022-12-3109930790core:ShareCapital2023-12-3109930790core:SharePremium2023-12-3109930790core:RevaluationReserve2023-12-3109930790core:OtherReservesSubtotal2023-12-3109930790core:RetainedEarningsAccumulatedLosses2023-12-3109930790core:ShareCapital2022-12-3109930790core:SharePremium2022-12-3109930790core:RevaluationReserve2022-12-3109930790core:OtherReservesSubtotal2022-12-3109930790core:RetainedEarningsAccumulatedLosses2022-12-3109930790core:LandBuildings2023-12-3109930790core:PlantMachinery2023-12-3109930790core:Vehicles2023-12-3109930790core:FurnitureFittings2023-12-3109930790core:OfficeEquipment2023-12-3109930790core:NetGoodwill2023-12-3109930790core:IntangibleAssetsOtherThanGoodwill2023-12-3109930790core:ListedExchangeTraded2023-12-3109930790core:UnlistedNon-exchangeTraded2023-12-3109930790core:LandBuildings2022-12-3109930790core:PlantMachinery2022-12-3109930790core:Vehicles2022-12-3109930790core:FurnitureFittings2022-12-3109930790core:OfficeEquipment2022-12-3109930790core:NetGoodwill2022-12-3109930790core:IntangibleAssetsOtherThanGoodwill2022-12-3109930790core:ListedExchangeTraded2022-12-3109930790core:UnlistedNon-exchangeTraded2022-12-3109930790core:LandBuildings2023-01-012023-12-3109930790core:PlantMachinery2023-01-012023-12-3109930790core:Vehicles2023-01-012023-12-3109930790core:FurnitureFittings2023-01-012023-12-3109930790core:OfficeEquipment2023-01-012023-12-3109930790core:NetGoodwill2023-01-012023-12-3109930790core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3109930790core:ListedExchangeTraded2023-01-012023-12-3109930790core:UnlistedNon-exchangeTraded2023-01-012023-12-3109930790core:MoreThanFiveYears2023-01-012023-12-3109930790core:Non-currentFinancialInstruments2023-12-3109930790core:Non-currentFinancialInstruments2022-12-3109930790dpl:CostSales2023-01-012023-12-3109930790dpl:DistributionCosts2023-01-012023-12-3109930790core:LandBuildings2023-01-012023-12-3109930790core:PlantMachinery2023-01-012023-12-3109930790core:Vehicles2023-01-012023-12-3109930790core:FurnitureFittings2023-01-012023-12-3109930790core:OfficeEquipment2023-01-012023-12-3109930790dpl:AdministrativeExpenses2023-01-012023-12-3109930790core:NetGoodwill2023-01-012023-12-3109930790core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3109930790dpl:GroupUndertakings2023-01-012023-12-3109930790dpl:ParticipatingInterests2023-01-012023-12-3109930790dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-012023-12-3109930790core:ListedExchangeTraded2023-01-012023-12-3109930790dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-012023-12-3109930790core:UnlistedNon-exchangeTraded2023-01-012023-12-3109930790dpl:CostSales2022-01-012022-12-3109930790dpl:DistributionCosts2022-01-012022-12-3109930790core:LandBuildings2022-01-012022-12-3109930790core:PlantMachinery2022-01-012022-12-3109930790core:Vehicles2022-01-012022-12-3109930790core:FurnitureFittings2022-01-012022-12-3109930790core:OfficeEquipment2022-01-012022-12-3109930790dpl:AdministrativeExpenses2022-01-012022-12-3109930790core:NetGoodwill2022-01-012022-12-3109930790core:IntangibleAssetsOtherThanGoodwill2022-01-012022-12-3109930790dpl:GroupUndertakings2022-01-012022-12-3109930790dpl:ParticipatingInterests2022-01-012022-12-3109930790dpl:GroupUndertakingscore:ListedExchangeTraded2022-01-012022-12-3109930790core:ListedExchangeTraded2022-01-012022-12-3109930790dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-01-012022-12-3109930790core:UnlistedNon-exchangeTraded2022-01-012022-12-3109930790core:NetGoodwill2023-12-3109930790core:IntangibleAssetsOtherThanGoodwill2023-12-3109930790core:LandBuildings2023-12-3109930790core:PlantMachinery2023-12-3109930790core:Vehicles2023-12-3109930790core:FurnitureFittings2023-12-3109930790core:OfficeEquipment2023-12-3109930790core:AfterOneYear2023-12-3109930790core:WithinOneYear2023-12-3109930790core:ListedExchangeTraded2023-12-3109930790core:UnlistedNon-exchangeTraded2023-12-3109930790core:ShareCapital2023-12-3109930790core:SharePremium2023-12-3109930790core:RevaluationReserve2023-12-3109930790core:OtherReservesSubtotal2023-12-3109930790core:RetainedEarningsAccumulatedLosses2023-12-3109930790core:NetGoodwill2022-12-3109930790core:IntangibleAssetsOtherThanGoodwill2022-12-3109930790core:LandBuildings2022-12-3109930790core:PlantMachinery2022-12-3109930790core:Vehicles2022-12-3109930790core:FurnitureFittings2022-12-3109930790core:OfficeEquipment2022-12-3109930790core:AfterOneYear2022-12-3109930790core:WithinOneYear2022-12-3109930790core:ListedExchangeTraded2022-12-3109930790core:UnlistedNon-exchangeTraded2022-12-3109930790core:ShareCapital2022-12-3109930790core:SharePremium2022-12-3109930790core:RevaluationReserve2022-12-3109930790core:OtherReservesSubtotal2022-12-3109930790core:RetainedEarningsAccumulatedLosses2022-12-3109930790core:NetGoodwill2022-01-0109930790core:IntangibleAssetsOtherThanGoodwill2022-01-0109930790core:LandBuildings2022-01-0109930790core:PlantMachinery2022-01-0109930790core:Vehicles2022-01-0109930790core:FurnitureFittings2022-01-0109930790core:OfficeEquipment2022-01-0109930790core:AfterOneYear2022-01-0109930790core:WithinOneYear2022-01-0109930790core:ListedExchangeTraded2022-01-0109930790core:UnlistedNon-exchangeTraded2022-01-0109930790core:ShareCapital2022-01-0109930790core:SharePremium2022-01-0109930790core:RevaluationReserve2022-01-0109930790core:OtherReservesSubtotal2022-01-0109930790core:RetainedEarningsAccumulatedLosses2022-01-0109930790core:AfterOneYear2023-01-012023-12-3109930790core:WithinOneYear2023-01-012023-12-3109930790core:Non-currentFinancialInstrumentscore:CostValuation2023-01-012023-12-3109930790core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-01-012023-12-3109930790core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-01-012023-12-3109930790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-01-012023-12-3109930790core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-01-012023-12-3109930790core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-01-012023-12-3109930790core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3109930790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3109930790core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3109930790core:Non-currentFinancialInstrumentscore:CostValuation2023-12-3109930790core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-3109930790core:Non-currentFinancialInstrumentscore:CostValuation2022-12-3109930790core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-12-3109930790core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-12-3109930790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-12-3109930790core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-12-3109930790core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-12-3109930790core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-12-3109930790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-12-3109930790core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-12-3109930790bus:Director12023-01-012023-12-31

Sahli Medical Limited

Registered Number
09930790
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2023

Sahli Medical Limited
Company Information
for the year from 1 January 2023 to 31 December 2023

Director

Dr Alaa Hassan

Company Secretary

Soha Khalifa

Registered Address

29 Bishops Way
Dalston
Carlisle
CA5 7LF

Registered Number

09930790 (England and Wales)
Sahli Medical Limited
Statement of Financial Position
31 December 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Tangible assets38671,020
8671,020
Current assets
Debtors3,6003,550
Cash at bank and on hand145,479122,284
149,079125,834
Creditors amounts falling due within one year6(105,633)(93,968)
Net current assets (liabilities)43,44631,866
Total assets less current liabilities44,31332,886
Net assets44,31332,886
Capital and reserves
Called up share capital55
Profit and loss account44,30832,881
Shareholders' funds44,31332,886
The financial statements were approved and authorised for issue by the Director on 2 April 2024, and are signed on its behalf by:
Dr Alaa Hassan
Director
Registered Company No. 09930790
Sahli Medical Limited
Notes to the Financial Statements
for the year ended 31 December 2023

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Judgements and key sources of estimation uncertainty
Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. There are no key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Plant and machinery15
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Financial instruments
The company only holds basic financial instruments as defined in FRS 102. The financial assets and financial liabilities of the company and their measurement basis are as follows: Financial assets – trade and other debtors are basic financial instruments and are debt instruments measured at amortised cost as detailed in notes. Prepayments are not financial instruments. Cash at bank – is classified as a basic financial instrument and is measured at face value. Financial liabilities – trade creditors, accruals and other creditors are financial instruments, and are measured at amortised cost as detailed in notes. Taxation and social security are not included in the financial instruments disclosure definition. Deferred income is not deemed to be a financial liability, as the cash settlement has already taken place and there is an obligation to deliver services rather than cash or another financial instrument.
2.Average number of employees

20232022
Average number of employees during the year33
3.Tangible fixed assets

Plant & machinery

Total

££
Cost or valuation
At 01 January 232,6082,608
At 31 December 232,6082,608
Depreciation and impairment
At 01 January 231,5881,588
Charge for year153153
At 31 December 231,7411,741
Net book value
At 31 December 23867867
At 31 December 221,0201,020
4.Impairment of tangible fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.
5.Debtors: amounts due within one year

2023

2022

££
Trade debtors / trade receivables3,6003,550
Total3,6003,550
6.Creditors: amounts due within one year

2023

2022

££
Taxation and social security3,8895,979
Other creditors101,14487,388
Accrued liabilities and deferred income600601
Total105,63393,968
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.